A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.
about
Potential Roles of Fungal Extracellular Vesicles during InfectionSelf-assembling protein nanoparticles in the design of vaccinesHow Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsNew insights on the development of fungal vaccines: from immunity to recent challengesStudies of Immune Responses in Candida vaginitisExperimental Models of Vaginal Candidiasis and Their Relevance to Human CandidiasisIL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasisCandida vaginitis: when opportunism knocks, the host respondsFungal vaccines and immunotherapeutics.Liposomes as vaccine delivery systems: a review of the recent advances.Secretory Aspartyl Proteinases Cause Vaginitis and Can Mediate Vaginitis Caused by Candida albicans in Mice.Vaccines in the treatment of invasive candidiasis.New approaches in the development of a vaccine for mucosal candidiasis: progress and challengesRecent progress in vaccines against fungal diseasesAspartyl Proteinases of Eukaryotic Microbial Pathogens: From Eating to HeatingGenetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.Hybrid phage displaying SLAQVKYTSASSI induces protection against Candida albicans challenge in BALB/c miceInnate immune cell response upon Candida albicans infectionInfluenza virosomes as vaccine adjuvant and carrier system.Candida antigens and immune responses: implications for a vaccine.Advanced topical drug delivery system for the management of vaginal candidiasis.Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.The protective role of immunoglobulins in fungal infections and inflammation.Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches.A novel mechanism behind the immunopathogenesis of vulvovaginal candidiasis: "Neutrophil Anergy".The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future.Candida Immunity
P2860
Q26743448-05BB459F-72A9-4B69-879B-BF52041D135DQ26767097-9BE60EBA-FFAF-4CF7-B01E-6BDDB3F8F437Q26771113-F94B0C05-4740-45C5-9B09-90FB7C1A5F8AQ26776056-556F1CEB-80E6-4F27-9FF0-A02C42DA9913Q26782272-213F2FB1-061B-4E98-AD31-51CD8129A33CQ28077299-735F4534-A2F3-4A4D-9CE9-79A639EE6463Q28534626-F07AE18F-8F77-4728-89BB-31B32CB5B281Q31157510-1FE55A28-C4E7-4A9A-A89D-F7ECA27AFDD2Q34400249-B46E44D5-A457-4FDA-92C4-695C99A1DB2AQ34418761-9D47BA8E-3879-4CCD-A537-A813908D02D2Q35650359-CF39ADCA-93EE-4FAB-A2C4-B98BECD72494Q36147010-201A95BA-3336-4E59-9D15-A937268D8E0CQ36158337-BBE9CBD0-992A-4D6D-870B-6B3FB5195253Q36179629-109B1997-3429-403A-9B23-724D40A768BBQ36231575-CEC5069F-C0BC-4658-85E3-673BD760B6BAQ36788780-38263E1D-6720-4F07-BACE-A16056DE10B3Q36977827-88698BBF-9A42-4456-AC89-137F3BA7EDB4Q37262877-685A2858-FE5D-4894-B37C-51109AE6A113Q38124062-0BD768D8-BCB1-4C5D-AA85-CD56D694E7D1Q38222636-EBEC06C4-9667-4E77-B320-BFC6118555FAQ38222794-7E509C70-849B-4A99-B6B0-EA3B5597FD35Q38232781-8E4B9F1E-DE9B-4B79-95A8-6F8017C68BACQ38264288-D764CC4C-EA71-40B5-B5A1-4C9D313A5ECAQ38268922-C756E456-005C-4C56-B64B-03A89EADFC70Q38363105-2E31649A-5976-4841-900C-207C23816E69Q38696236-5D309218-C8D9-4F1E-848E-59BDAD93A895Q50083006-14498DFE-E807-43D1-B15F-8908A4588482Q53683158-BC116A47-9B37-48F7-A2FF-05FD31A8CC55Q59072636-775B488A-F3CE-4C39-8D79-0B8A486AAE59
P2860
A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A virosomal vaccine against ca ...... fety profile in animal models.
@en
A virosomal vaccine against ca ...... fety profile in animal models.
@nl
type
label
A virosomal vaccine against ca ...... fety profile in animal models.
@en
A virosomal vaccine against ca ...... fety profile in animal models.
@nl
prefLabel
A virosomal vaccine against ca ...... fety profile in animal models.
@en
A virosomal vaccine against ca ...... fety profile in animal models.
@nl
P2093
P1433
P1476
A virosomal vaccine against ca ...... afety profile in animal models
@en
P2093
Antonio Cassone
Christel Gremion
Christian Moser
Flavia De Bernardis
Mario Amacker
Rinaldo Zurbriggen
P304
P356
10.1016/J.VACCINE.2012.04.069
P407
P577
2012-05-03T00:00:00Z